



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mattheakis et al.

Attorney Docket No.: CYTOP135

Application No.: 10/623,486

Examiner: LILLING, HERBERT J

Filed: July 18, 2003

Group: 1651

Title: PREDICTING HEPATOTOXICITY USING
CELL BASED ASSAYS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first-class mail on April 15, 2005 in an envelope addressed to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Signed: _____

Joyce L. Ferreira

**INFORMATION DISCLOSURE STATEMENT
37 CFR §§1.56 AND 1.97(b)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

The references listed in the attached PTO Form 1449, copies of which are attached, may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application.


This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is: (i) filed within three (3) months of the filing date of the above-referenced application, (ii) believed to be filed before the mailing date of a first Office Action on the merits, or (iii) believed to be filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. CYTOP0135).

Respectfully submitted,
BEYER WEAVER & THOMAS, LLP


Jeffrey K. Weaver
Registration No. 31,314

P.O. Box 70250
Oakland, CA 94612-0250



Form 1449 (Modified)	Atty Docket No. CYTOP135	Application No.: 10/623,486
Information Disclosure Statement By Applicant	Applicant: Mattheakis et al.	
(Use Several Sheets if Necessary)	Filing Date July 18, 2003	Group Unassigned

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	1A	D.L. Taylor, "The new vision of light microscopy", American Scientist 80:322-335, 1992
	2A	K. A. Giuliano et al., "Measurement and manipulation of cytoskeletal dynamics in living cells", Current Opinion in Cell Biology 7:4-12, 1995
	3A	BioDx, Internet Archive Way-Back Machine, February 4, 1997 From website www.biodx.com
	4A	A. Waggoner et al., "Multiparameter Fluorescence imaging microscopy: reagents and instruments" Human Pathology, Vol. 27, No. 5, 494-502, 1996
	5A	Benveniste et al., "Characterization of Internalization and endosome formation of epidermal growth factor in transfected NIH-3T3 cells by computerized image-intensified three-dimensional fluorescence microscopy", The Journal of Cell Biology 109: 2105-2115, 1989
	6A	K.L. Carey et al., "Evidence using a green fluorescent protein-glucocorticoid receptor chimera that the RAN/TC4 GTPase mediates an essential function independent of nuclear protein import", The Journal of Cell Biology, Vol. 133, No. 5, 985-996, 1996
	7A	J. Kolega et al., "Quantitation of cytoskeletal fibers in fluorescence images: stress fiber disassembly accompanies dephosphorylation of the regulatory light chains of myosin II", Bioimaging 1:136-150, 1993
	8A	D.L Farkas et al., "Multimode light microscopy and the dynamics of molecules, cells, and tissues", Annu. Rev. Physiol. 55:785-817, 1993
	9A	W. Böcker et al., Automated cell cycle analysis with fluorescent microscopy and image analysis", Phys. Med. Biol. 41:523-537, 1996
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449 (Modified) Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)	Atty Docket No.	Application No.:
	CYTOP135	10/623,486
	Applicant: Mattheakis et al.	
Filing Date	Group	
July 18, 2003	Unassigned	

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	1B	R. Pepperkok et al., "System for quantitation of gene expression in single cells by computerized microimaging: Application to c-fos expression after microinjection of anti-casein kinase II antibody", Experimental Cell Research 204:278-285, 1993
	2B	F. Hanakam, "Myristoylated and non-myristoylated forms of the pH sensor protein hisactophilin II: intracellular shuttling to plasma membrane and nucleus monitored in real time by a fusion with green fluorescent protein", The EMBO Journal 15(12):2935-43, 1996
	3B	N.B. Cole, "Golgi Dispersal during microtubule disruption: Regeneration of Golgi stacks at Peripheral Endoplasmic Reticulum Exit sites," Molecular Biology of the Cell, Vol. 7, 631-650, 1996
	4B	B.M. Machiels Subcellular localization of proteasomes in apoptotic lung tumor cells and persistence as compared to intermediate filaments" European Journal of Cell Biology 70:250-259, 1996
	5B	N. Yasuhara et al., "Essential Role of active nuclear transport in apoptosis" Genes to Cells 2:55-64, January 1997
	6B	BioDx, Inc., Internet archive, way back machine May 21, 1997 From website www.biodx.com
	7B	M.V. Rogers, "Light on high -throughput screening: fluorescence-based assay technologies", Drug Discovery Today, Vol. 2, No. 4, 156-160 April 1997
	8B	W. Böcker et al., "Image Processing algorithms for the automated micronucleus assay in binucleated human lymphocytes", Cytometry 19:283-294 (1995)
	9B	Lansing D. Taylor, U.S. Provisional application No. 60/018,696, filed May 30, 1996
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.